Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients

Pediatric Transplantation

Volumn 9, Issue 2, 2005, Pages 162-169

  Kim, Jung Sue ^b   Aviles, Diego H ^a   Silverstein, Douglas M ^a   LeBlanc, Pamela L ^a   Vehaskari, V Matti ^a,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b St Mary's Hospital   (South Korea)

^c CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Ethnicity; Kidney transplant; Pharmacokinetics; Steroid free immunosuppression; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; DACLIZUMAB; GLUCOCORTICOID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADOLESCENT; AFRICAN AMERICAN; AGE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; ETHNOLOGY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE;

AFRICAN AMERICANS; AGE FACTORS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS;

EID: 16444367741     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00263.x     Document Type: Article

References (41)

1. FILLER G, GRYGAS R, MAI I, et al. Pharmacokinetic of tacrolimus (FK-506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997: 12: 1668-1671.
2. UEMOTO S, TANAKA K, HONDA K, et al. Experience with FK506 in living-related liver transplantation. Transplantation 1993: 55: 288-291.
3. LASKOW DA, VINCENTI F, NEYLAN JF, MENDEZ R, MATAS AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996: 65: 900-905.
4. NARPTCS. 2002 Annual Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). 2002, Section 3.
5. NEU AM, HO PL, FINE RN, FURTH SL, FIVUSH BA. Tacrolimus vs. cyclosporin A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003: 7: 217-222.
6. SMITH JM, NEMETH TL, MCDONALD RA. Current immunosuppressive agents: efficacy, side effects, utilization. Pediatr Clin North Am 2003: 50: 1283-1300.
7. FILLER G. TROMPETER R, WEBB NJ. et al. One-year glomerular filtration rate graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. Transplant Proc 2002: 34: 1935-1938.
8. PETERS DH, FITTON A, PLOSKER GL, FAULDS D. Tacrolimus. A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993: 46: 746-794.
9. STAATZ CE, WILLIS C, TAYLOR PJ, TETT SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002: 72: 660-669.
10. UNDRE NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003: 18(Suppl. 1): i12-i15.
11. UNDRE NA. STEVENSON P, SCHAFER A. Pharmacokinetics of tacrolimus: clinical relevant aspects. Transplant Proc 1999: 31 (Suppl. 7A): S21-S24.
12. UNDRE NA, VAN HOOFF J, CHRISTIAANS M. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999: 31: 296-298.
13. DEL MAR FERNANDEZ DE GATTA M, SANTOS-BUELGA D, DOMINGUEZ-GIL A, GARCIA MJ. Immunosuppressive therapy for pediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002: 41: 115-135.
14. MOCHON M, COONEY G, LUM B, et al. Pharmacokinetics of cyclosporine after renal transplant in children. J Clin Pharmacol 1996: 36: 580-586.
15. COONEY GF, HABUCKY K, HOPPU K. Cyclosporine pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997: 32: 481-495.
16. SHISHIDO S, ASANUMA H, TAJIMA E, HONDA M, NAKAI H. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 2001: 33: 1066-1068.
17. USHIGOME H, OKAMOTO M. KADOTANI Y, et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. Transplant Proc 2003: 35: 165-166.
18. HASEGAWA A, TAKHASHI K, ITO K, OSHTMA S, UCHIDA K, SONODA T, for the Japanese Tacrolimus Study Group. Optimal use of tacrolimus in living donor renal transplantation in children. Transplant Proc 2002: 34: 1939-1941.
19. WEBB NJA, STEVENSON PJ, LEWIS MA, POSTIETHWAITE RJ, BRADBURY MG, UNDRE NA. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 2002: 34: 1948-1950.
20. ELLIS D, SHAPIRO R, JORDAN ML, et al. Comparison of FK506 and cyclosporin regimens in pediatric renal transplantation. Pediatr Nephrol 1994: 8: 193-200.
21. DUNN TB, ASOLATI M, HOLMAN DM, et al. Long-term outcomes of a prospective trial of steroid withdrawal after kidney transplantation. Surgery 1999: 125: 155-159.
22. MAIORCA R, CRISTINELLI L, BRUNORI G, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporin. Transplant Proc 1988: 20(Suppl. 3): 121-125.
23. RATCLIFFE PJ, DUDLEY CR, HIGGINS RM, FIRTH JD, SMITH B, MORRIS PJ. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996: 348: 643-648.
24. CHAKRABARTI P, WONG HY, SCANTLEBURY VP, et al. Outcome after steroid withdrawal in pediatric renal transplantation patients receiving tacrolimus-based immunosuppression. Transplantation 2000: 70: 760-764.
25. SARWAL MM, YOGIN PD, ALEXANDER S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2002: 72: 13-21.
26. SARWAL MM, VIDHUN J, ALEXANDER SR, SATTERWHITE T, MILLAN M, SALVATIERRA O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003: 76: 1331-1339.
27. VAN DUIJNHOVEN EM, BOOTS JMM, CHRISTIAANS MHL, UNDRE NA, VAN HOOFF JP. Tacrolimus trough levels increase after steroid withdrawal. Transplant Int 2003: 16: 721-725.
28. SQUIFFLET J-P, VANRENTERGHEM Y, VAN HOOFF JP, SALMELA K, RIGOTTI P, the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002: 34: 1584-1586.
29. ANGLICHEAU D, FLAMANT M, SCHLAGETER MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003: 18: 2409-2414.
30. SCHWARTZ GJ, HAYCOCK GB, EDELMANN CM, SPITZER A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976: 58: 259-263.
31. FILLER G, FEBER J, LEPAGE N, WEILER G, MAI I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002: 6: 411-418.
32. McALISTER VC, MAHALATI K, PELTEKIAN KM, FRASER A, MAcDoNALD AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002: 24: 346-350.
33. KIMIKAWA M, KAMOYA K, TOMA H, TERAOKA S. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant 2001: 15: 324-329.
34. BALBONTIN FG, KIBERD B, SQUIRES J, et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc 2003: 35: 2445-2448.
35. MACCHI-ANDERSON M, CHARPIAT B, JELLIFFE RW, DUCERF C, FOURCADE N, BAULIEUX J. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001: 23: 129-133.
36. OHLMAN S, LINDHOLM A, HAGGLUND H, SAWE J, KAHAN BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993: 44: 265-269.
37. BARALDO M, RISALITI A, BRESADOLA F, CHIARANDINI P, DALLA ROCCA G, FURLANUT M. Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation. Transplant Proc 2003: 35: 1449-1551.
38. MIN DI, CHEN HY, FABREGA A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996: 62: 1190-1192.
39. MANCINELLI LM, FRASSETTO L, FLOREN LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001: 69: 24-31.
40. WALLEMACQ PE, VERBEECK RK. Comparative clinical pharmacokinetics of tacrolimus in pediatric and adult patients. Clin Pharmacokinet 2001: 40: 283-295.
41. VAZQUEZ MA. Southwestern Internal Medicine Conference. New advances in immunosuppression therapy for renal transplantation. Am J Med Sci 1997: 314: 415-435.